The AtriCure Minimally Invasive Platform Highlighted By Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France
WEST CHESTER, Ohio, June 20 /PRNewswire-FirstCall/ — AtriCure, Inc. , a medical device company and a leader in cardiac surgical ablation systems, today announced that its minimally invasive platform was highlighted during Cardiostim, a world congress in cardiac electrophysiology and cardiac techniques. On June 18, Dr. Kenneth Ellenbogen, Vice Chairman of Cardiology and Director of Clinical Cardiac Electrophysiology and Pacing at the Medical College of Virginia, chaired a symposium entitled “The Epicardial Frontier: Minimally Invasive Ablation for Atrial Fibrillation.”
The session focused on the current indications and investigation of the AtriCure minimally invasive platform as a treatment alternative for atrial fibrillation, or AF. Dr. Vigneshwar Kasirajan, a leading cardiothoracic surgeon and colleague of Dr. Ellenbogen, presented their patient selection criteria and patient results. Dr. Wim Jan van Boven, a leading European cardiothoracic surgeon, presented his experience utilizing the AtriCure minimally invasive platform to perform 125 totally thoracoscopic ablation procedures. In this impressive totally thoracoscopic series, the procedure times reported were routinely 60 minutes and patients were discharged from the hospital in two days or less. Additionally, Dr. Warren Jackman, a pioneer in arrhythmia research, presented the importance of electrophysiology mapping during surgical ablation and the expanding role of this minimally invasive platform as a treatment alternative for chronic AF patients.
“There is a growing interest in this minimally invasive approach within the electrophysiology community as a treatment alternative for a subset of patients that are generally not candidates for catheter ablation procedures,” said Dr. Ellenbogen. “Additionally, we are enthusiastic regarding our investigation of an expanded ablation procedure using the Coolrail(TM) system for patients with persistent and long standing persistent AF.” Dr. Kasirajan commented, “In our experience the results using this minimally invasive approach are very encouraging. We are actively working with AtriCure to further optimize these products and minimally invasive techniques.”
David J. Drachman, AtriCure’s President and Chief Executive Officer commented, “This symposium highlighted our building momentum resulting from our highly encouraging minimally invasive sole-therapy, off-pump clinical results which, importantly, are based on the use of long-term continuous monitoring. Procedure times of 60 minutes and patients discharged from the hospital at two days or less, combined with our clinical results are clear indicators of our large and growing opportunity.”
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure’s multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure’s multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure’s products for the treatment of AF. AtriCure’s left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 email@example.com
CONTACT: Julie A. Piton, Vice President and Chief Financial Officer ofAtriCure, Inc., +1-513-755-4561, firstname.lastname@example.org
Web site: http://www.atricure.com/